Navigation Links
Hybrid Nanoparticles for Multimodal Medical Imaging

Since X-rays were discovered more than a century ago, triggering a revolution in medical imaging, clinicians have sought more powerful ways to "see" into the human body.//

Now, with a $1.1 million grant from the John R. Oishei Foundation, researchers in the University at Buffalo's Institute for Lasers, Photonics and Biophotonics are turning their expertise in nanomedicine to the development of new, nanoparticle-based multi-probe systems, launching a new generation of medical imaging. The grant will fund research in which two or more medical imaging techniques are combined to provide complementary information.

Part of a new field called nanobiotechnology, the UB scientists are designing these nanoparticle systems to contain multiple contrast agents for different imaging medical techniques.

The goal is to diagnose cancer and other diseases in their earliest stages by providing far more comprehensive data to clinicians.

"Ultimately, clinicians want the most complete data possible that they can gather from medical images, ranging from tissue structure to metabolic processes to molecular markers," said Paras Prasad, Ph.D., executive director of the Institute for Lasers, Photonics and Biophotonics and SUNY Distinguished Professor of Chemistry.

"We are aiming to provide them with such data by developing nanoparticle platforms capable of carrying multiple contrast agents for complementary medical imaging techniques in the same nano-sized package," he said.

Once injected with these multimodal nanoparticles, the patient can undergo several imaging tests, the results of which will be combined to provide more comprehensive and complementary information, such as correlations between molecular and morphological changes at the cellular level.

The result is a far more sensitive and comprehensive method of detecting the presence or progression of a disease.

"At the same time, these imagin g agents will provide pharmaceutical researchers and clinicians with powerful tools for more precise monitoring and tracking of drug action in real-time," said Prasad.

The multimodal platforms underway in Prasad's group are based on versatile nanoparticles that the UB researchers have developed with previous Oishei Foundation funding that have been shown to be effective in a broad range of therapeutic applications.

"The fields of nanomedicine in which Dr. Prasad and his teams are working are developing extremely rapidly, and they are at the forefront," said Thomas E. Baker, president of the foundation. "The work of these grants has tremendous potential for significantly improving both the diagnostic capabilities of physicians and the clinical outcomes of patients."

The research also is being conducted with partial funding from UB's New York State Center of Excellence in Bioinformatics and Life Sciences, a major supporter of the nanomedicine program at the Institute for Lasers, Photonics and Biophotoncs. Prasad is affiliated with the Bioengineering/Tissue Engineering Team at the Center of Excellence.

"This new imaging work represents an exciting and timely extension of our existing nanomedicine portfolio that will be particularly important for the Center of Excellence initiatives in neurodegenerative disease and cancer," said Bruce A. Holm, UB senior vice provost and executive director of the Center of Excellence. "This research not only crosses a variety of UB 2020 Strategic Strength areas, but holds enormous promise for commercialization potential as well."

The UB institute's new emphasis on application of nanobiotechnology to medical imaging also distinguishes it from other nanotechnology research centers throughout the U.S., while enriching its current collaborations with The Johns Hopkins University, Roswell Park Cancer Institute and others.

The nanoprobes are being developed for use with: < br>
-- Optical imaging techniques, especially those in which fluorescence and Raman scattering can probe the intracellular distribution of molecular events that are early signals of disease or responses to drugs.

-- Magnetic resonance imaging (MRI), in which fluorine nuclear probes would be developed using the nanoparticles, providing more selective targeting of specific biological sites.

-- Positron emission tomography (PET), in which radioisotopes are incorporated inside nanoparticles as contrast agents for more sensitive assessments of drug efficacy during therapy.

-- Computed tomography (CT) and single photon emission computer tomography (SPECT), in which radio-opaque ions are incorporated inside nanoparticles as contrast agents for improved in vivo imaging.

The Oishei grant, "Developing New Advances in Medical Imaging through Nanotechnology," will be used in part to recruit and support a research professor to provide expertise in ultrasound imaging, as well as postdoctoral fellows and graduate students who will focus on the development of multimodal nanoprobes for medical imaging.

Source-Newswise
'"/>




Related medicine news :

1. Hybrid antibodies to protect from small pox infection
2. NHS To Be Reformed By Using A Hybrid Approach
3. Molecular Imaging Of Cancer Now Possible, New Hybrid Virus Produced
4. Hybrid Molecule Causes Cancer Cells to Self-Destruct
5. Gold Nanoparticles: Agents For Noninvasive Cancer Therapy
6. Alzheimers Can Be Slowed Down By Gold Nanoparticles
7. Gold Nanoparticles Are Good Detectors Biological Toxins
8. Scientists To Study Effect Of Nanoparticles On Liver
9. Nanoparticles and Their Damage to Liver Cells
10. Effect of Nanoparticles on Liver
11. Use of Nanoparticles in Sunscreen under Scrutiny
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: